

Notice

An Act respecting prescription drug insurance
(chapter A-29.01)

End of insurance coverage of medications

HAVING REGARD TO section 60.0.4 of the Act respecting prescription drug insurance
(chapter A-29.01);

HAVING REGARD TO the power of the Minister to suspend the insurance coverage of a medication, to end it or to not re-enter it, notably where a medication is subject to a listing agreement;

CONSIDERING that generic drugs competing with a generic drug of the manufacturer GlaxoSmithKline Inc. are the subject to a listing agreement pursuant to subparagraph 3 of paragraph 1 of section 60.0.4 of the Act respecting prescription drug insurance;

CONSIDERING that these competing generic drugs are produced by the following manufacturers:

Competing manufacturers	DIN	Brand name	Form	Strength
Jamp Pharma Corporation	80024835	Jamp-Potassium Chloride	Oral Solution	6.65 mmol/5 mL (in K+)
Pharmascience Inc.	2238604	pms-Potassium Chloride	Oral Solution	6.65 mmol/5 mL (in K+)

The Minister of Health and Social Services hereby gives notice of the end of the insurance coverage of the following generic drug of the manufacturer GlaxoSmithKline Inc.:

Manufacturer	DIN	Brand name	Form	Strength	Size
GlaxoSmithKline Inc.	80024360	K-10	Oral Solution	6.65 mmol/5 mL (in K+)	500

This notice will come into force on 15 December 2017.

Québec, 29 November 2017

Original signed by

GAÉTAN BARRETTE
Minister of Health and Social Services